Checkpoint Inhibitors in Oncology Practice: Optimizing Therapy, Preventing and Managing Immune-Related Adverse Events

Released On
December 30, 2020

Expires On
February 27, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Hematology-Oncology

Topic(s)
Leukemia

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Practicing Clinicians Exchange.

This activity was developed from a series of programs cosupported by educational grants from Astellas; Astellas and Pfizer, Inc; Bristol-Myers Squibb; Celgene Corporation; Eisai Inc; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc, administered by Pharmacyclics, LLC; Taiho Oncology, Inc; and Sanofi Genzyme.

This activity is supported by an educational grant from Bristol-Myers Squibb.

Credit Available

  • Physicians — maximum of 1.00 AMA PRA Category 1 Credit(s)
  • Pharmacists — maximum of 1.0 contact hours (0.10 CEUs)
  • Nurses — 1.00 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of Oncology NPs, PAs, and nurses.

Program Overview

Immune checkpoint inhibitors—alone or in combination with other therapies—are revolutionizing the treatment of cancer across a wide range of tumor types. Because these agents are rapidly emerging into clinical practice, all members of the oncology treatment team need to have a thorough understanding of checkpoint inhibitors, including selection of therapy and identification and management of toxicities unique to checkpoint inhibitors. This activity provides an update on the most current therapies and strategies for their optimal use in clinical practice.

Learning Objectives

After completing this activity, participants should be better able to:

  • Describe the mechanisms of action of immune checkpoint inhibitors in cancer therapy
  • Summarize evidence for the roles of checkpoint inhibitors in clinical management of patients with cancer
  • Formulate strategies to identify and manage adverse events, toxicities, and adherence challenges associated with checkpoint inhibitors for treatment of cancer

Faculty

Beth Sandy, MSN, CRNP

Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Stephanie Andrews, MS, ANP-BC

Nurse Practitioner
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida

Joint Accreditation Statement

In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

ANCC Credit Designation
Course director: Lee Schwartzberg, MD, FACP, West Cancer Center, Germantown, Tennessee
CNE course advisor: Stephanie Andrews, MS, ANP-BC, Moffitt Cancer Center, Tampa, Florida
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

AAPA Credit Designation

Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until February 27, 2021. PAs should only claim credit commensurate with the extent of their participation.

 

PA course advisor: Emilee Thomas, MMS, MPH, PA-C, Weill Cornell Medicine, New York, New York

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

 

Disclosures of Conflicts of Interest

All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are expected to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Beth Sandy, MSN, CRNP

  • Speakers Bureau: AstraZeneca, Helsinn, Merck, Takeda

Stephanie Andrews, MS, ANP-BC

  • Consultant: Daiichi-Sankyo, OncoSec
  • Speakers Bureau: Genentech

Lee Schwartzberg, MD, FACP

  • Consultant: Amgen, AstraZeneca, Pfizer

None of the members of the CE Alliance staff have any relevant relationships to disclose.

Instructions for Participation and Credit

Participants wishing to earn CE/CME credit must::

  1. Read the content in its entirety.
  2. Relate the content material to the learning objectives.
  3. Complete the post-test and evaluation form.

 

Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.

The estimated time to complete this activity is 1.00 hour.

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, or any educational supporter.

Contact Information

For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.